Coherus Oncology (CHRS) EBIAT (2016 - 2025)
Coherus Oncology (CHRS) has disclosed EBIAT for 13 consecutive years, with -$37.6 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 119.03% to -$37.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $168.0 million through Dec 2025, down 30.04% year-over-year, with the annual reading at $168.0 million for FY2025, 489.41% up from the prior year.
- EBIAT hit -$37.6 million in Q4 2025 for Coherus Oncology, down from -$35.5 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $297.8 million in Q2 2025 to a low of -$172.9 million in Q1 2021.
- Historically, EBIAT has averaged -$20.4 million across 5 years, with a median of -$44.3 million in 2021.
- Biggest five-year swings in EBIAT: crashed 586.19% in 2021 and later skyrocketed 2404.52% in 2025.
- Year by year, EBIAT stood at -$45.7 million in 2021, then fell by 28.75% to -$58.9 million in 2022, then crashed by 35.3% to -$79.7 million in 2023, then surged by 348.34% to $197.8 million in 2024, then crashed by 119.03% to -$37.6 million in 2025.
- Business Quant data shows EBIAT for CHRS at -$37.6 million in Q4 2025, -$35.5 million in Q3 2025, and $297.8 million in Q2 2025.